FDA Approves Teplizumab: What This New Treatment Means for Children with Type 1 Diabetes

Type 1 diabetes develops gradually through distinct stages. The process involves autoantibodies—proteins made by the immune system that mistakenly attack the body's own cells. In Type 1 diabetes, these autoantibodies target insulin-producing cells in the pancreas. Key autoantibodies include insulin autoantibody, glutamic acid decarboxylase autoantibody, IA-2 autoantibody, and zinc transporter 8 autoantibody.

Stage 3 Type 1 diabetes is when a person has been recently diagnosed with high blood sugar levels and the immune system is actively destroying insulin-producing cells. This is the stage where teplizumab can now be used.

Teplizumab (Tzield) is a monoclonal antibody—a type of medication that targets specific parts of the immune system. It works by targeting a marker on T-cells, a key type of immune cell involved in attacking the pancreas in Type 1 diabetes. By modifying these immune cells, teplizumab aims to slow down the loss of insulin-producing function.

The medication is given through intravenous (IV) infusions. Patients receive treatment once daily for 12 consecutive days, followed by a second 12-day course of treatment six months later. This approach was tested in the PROTECT Study, a large clinical trial involving 328 children and teenagers.

The PROTECT Study was a randomized, double-blind, placebo-controlled trial, considered the gold standard for testing new treatments. This means patients were randomly assigned to receive either teplizumab or a placebo (inactive treatment), and neither the patients nor the research team knew which treatment each person was getting until the study ended.

The trial provided evidence that teplizumab can delay the progression of Type 1 diabetes in children and teenagers recently diagnosed with Stage 3 disease. Based on these results, the FDA approved teplizumab for children ages 8-17 in this stage of the disease.

A recent survey of adults and caregivers who received teplizumab found that 87% felt grateful to have access to the treatment. The primary reason people sought out and received teplizumab was for the opportunity to delay the onset of Stage 3 Type 1 diabetes or slow its progression.

Among survey respondents, 72% believed the treatment would help slow down the disease, and 60% thought it would make Type 1 diabetes easier to manage. Most respondents said they would recommend the treatment or make the same decision for another family member. However, respondents also noted that they continued to have concerns about disease progression even after receiving teplizumab.

The Pediatric Endocrine Society has emphasized that teplizumab is a new treatment for most pediatric endocrinologists, and guidance is still being developed regarding its use in clinical practice. Health care providers are working to establish best practices for patient selection, safety monitoring, and side effect management.

While teplizumab delays Type 1 diabetes progression, it is not a cure. Ongoing long-term studies are needed to continue evaluating how well and how safely the treatment works over time. Families interested in teplizumab should discuss with their diabetes care team whether this treatment might be appropriate for their child.

Origin: Biopharma from Technology Networks (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.